Improving quality control for CAR T cell therapies
Drug Discovery World
AUGUST 10, 2022
In 1987, researchers developed the chimeric antigen receptor (CAR) as an alternative means to identify cancer cells and direct T cells to attack them. And now, with more than 600 CAR T trials recruiting or ongoing, these cells represent a majority of the cellular immunotherapies in development today. Training T cells to target tumours.
246 
Let's personalize your content